Brad Canino
Stock Analyst at Guggenheim
(4.80)
# 1,016
Out of 5,182 analysts
26
Total ratings
86.96%
Success rate
32.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Initiates: Buy | $54 | $36.92 | +46.26% | 1 | Apr 15, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $40 → $38 | $15.29 | +148.53% | 2 | Mar 17, 2026 | |
| RLAY Relay Therapeutics | Maintains: Buy | $15 → $22 | $14.95 | +47.16% | 2 | Mar 13, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $72 → $68 | $15.23 | +346.49% | 2 | Feb 27, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $13.25 | +126.42% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $25.15 | +39.17% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.92 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $104.04 | +48.98% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.76 | +297.73% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $86.68 | +3.83% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $22.12 | +80.83% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $66.82 | +34.69% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $125.68 | -12.48% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $10.19 | +76.64% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.83 | +182.69% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.07 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $28.56 | +92.58% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $44.65 | -32.81% | 2 | Mar 31, 2021 |
Tyra Biosciences
Apr 15, 2026
Initiates: Buy
Price Target: $54
Current: $36.92
Upside: +46.26%
Olema Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $40 → $38
Current: $15.29
Upside: +148.53%
Relay Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $22
Current: $14.95
Upside: +47.16%
Janux Therapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $72 → $68
Current: $15.23
Upside: +346.49%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $13.25
Upside: +126.42%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $25.15
Upside: +39.17%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.92
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $104.04
Upside: +48.98%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.76
Upside: +297.73%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $86.68
Upside: +3.83%
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $22.12
Upside: +80.83%
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $66.82
Upside: +34.69%
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $125.68
Upside: -12.48%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $10.19
Upside: +76.64%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.83
Upside: +182.69%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.07
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $28.56
Upside: +92.58%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $44.65
Upside: -32.81%